Loading
OM
ONCOSEC MEDICAL Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by DALESANDRO MARGARET, was filed 25 Aug 2021.
ONCOSEC MEDICAL Inc: what insiders have been doing
ONCOSEC MEDICAL Inc belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). ONCOSEC MEDICAL Inc has had no insider filing for more than a year; the last one goes back to 9 February 2023.
The full history, which starts in 2011, counts 46 purchases against 59 sales.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
136
Thresholds
n/a
Buy Volume
€32M
46 ops. · all time
Sell Volume
€2M
59 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2013FY ended July 2013 · cache
Income statement
Net income-US$29.4M
Last declaration on 9 February 2023
Declarations136 total
40 shares@ US$1.371.3% of flowCommon StockSEC:0001493152-23-004168:0
283 shares@ US$0.372.7% of flowCommon StockSEC:0001493152-22-030744:0
284 shares@ US$0.714.9% of flowCommon StockSEC:0001493152-22-021536:0
274 shares@ US$0.835.4% of flowCommon StockSEC:0001493152-22-012337:0
409 shares@ US$0.887.9% of flowCommon StockSEC:0001493152-22-004150:0
343 shares@ US$1.7513.0% of flowCommon StockSEC:0001493152-21-027164:0
20,000 shares@ US$1.89100.0% of flowCommon StockSEC:0001493152-21-021268:0
Canonical exit: 21 Nov 2021 (T+90)
4,000 shares@ US$1.8832.5% of flowCommon StockSEC:0001493152-21-021154:1
Canonical exit: 21 Nov 2021 (T+90)
8,000 shares@ US$1.94100.0% of flowCommon StockSEC:0001493152-21-021154:0
Canonical exit: 18 Nov 2021 (T+90)
412 shares@ US$2.1819.0% of flowCommon StockSEC:0001493152-21-018477:0
13,613 shares@ US$3.16100.0% of flowCommon StockSEC:0001493152-21-015620:1
192,000 shares0Common StockSEC:0001493152-21-015620:0
453 shares@ US$4.8645.8% of flowCommon StockSEC:0001493152-21-010453:0
3,172 shares@ US$4.86100.0% of flowCommon StockSEC:0001493152-21-010454:0
1,409,838 shares@ US$3.4513.7% of flowCommon StockSEC:0000899243-21-016957:0
Canonical exit: 15 Jul 2021 (T+90)
281,968 shares@ US$3.452.7% of flowCommon StockSEC:0000899243-21-016957:1
Canonical exit: 15 Jul 2021 (T+90)
368,250 shares@ US$3.4527.6% of flowCommon StockSEC:0001493152-21-004553:0
8,750 shares0Common StockSEC:0001493152-21-002566:0
3,413 shares@ US$7.719.8% of flowCommon StockSEC:0001493152-21-002424:0
3,389,198 shares@ US$5.4551.2% of flowCommon StockSEC:0000899243-21-003455:0
Canonical exit: 25 Apr 2021 (T+90)
677,839 shares@ US$5.4510.2% of flowCommon StockSEC:0000899243-21-003455:1
Canonical exit: 25 Apr 2021 (T+90)
80,000 shares@ US$4.923429.4% of flowCommon StockSEC:0001213900-20-038888:0
50,000 shares@ US$5.104619.1% of flowCommon StockSEC:0001213900-20-038582:0
40,000 shares@ US$5.241615.6% of flowCommon StockSEC:0001213900-20-038261:0
10,999 shares@ US$5.24164.3% of flowCommon StockSEC:0001213900-20-038261:1
25 of 136 declarations
About ONCOSEC MEDICAL Inc
OncoSec Medical Incorporated (ticker: ONCS) was a U.S.-based biotechnology company historically listed on NASDAQ in the United States. Its SEC filings and company communications show headquarters locations over time including San Diego, California and later Pennington, New Jersey. OncoSec’s business was built around oncology innovation, specifically intratumoral immunotherapy paired with a proprietary electroporation drug-delivery system. The company traces its biotech operations to March 2011, when it acquired technology and related assets from Inovio Pharmaceuticals, while its corporate predecessor dates back to 2008 under the name Netventory Solutions, Inc. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1444307/000149315218014674/form10-k.htm))
The company’s core platform was ImmunoPulse® / OMS EP, designed to deliver plasmid DNA directly into solid tumors using electrical pulses. Its lead clinical candidate was TAVO™ (tavokinogene telseplasmid), a DNA-encoded interleukin-12 (IL-12) therapy intended to reshape the immunosuppressive tumor microenvironment and trigger systemic anti-tumor immunity. Historically, OncoSec advanced TAVO both as a monotherapy and in combination with PD-1 inhibitors, including Merck’s KEYTRUDA®, across programs in metastatic melanoma, triple-negative breast cancer, and squamous cell head and neck cancer. The company also explored additional tumor indications and a visceral lesion applicator for deep-seated tumors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1444307/000149315218014674/form10-k.htm))
Read moreShow less
From a competitive standpoint, OncoSec operated in the highly crowded clinical-stage oncology biotechnology segment, where differentiation depends on scientific validation, safety data, and partnership leverage rather than commercial scale. Its investment case historically relied on the novelty of local electroporation-based delivery and the potential for combination therapy with checkpoint inhibitors. OncoSec received important FDA designations in 2017 for TAVO in metastatic melanoma, which supported the development story and underscored the program’s regulatory interest. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1444307/000149315218014674/form10-k.htm))
Recent company-defining events materially changed the risk profile. SEC filings show Nasdaq non-compliance notices in 2022 and 2023, followed by a voluntary Chapter 7 bankruptcy filing on June 14, 2023, and a subsequent Nasdaq delisting notice. For investors, this is a critical point: ONCS should be viewed as a distressed former NASDAQ-listed biotech in the United States, with severe liquidity, dilution, and going-concern risk rather than as a mature commercial healthcare business. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1444307/000149315223005743/form8-k.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
